Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Lubbock, Texas 79430


This study is being conducted to compare the effects that 2 different combinations of heart failure medications have on the levels of certain blood markers which cause and/or worsen heart failure. Additionally, the investigators will investigate any differences that may exist between Hispanics and Non-Hispanics. The investigators hope to find that Hispanic Americans will have a greater response to this new regimen compared to non-Hispanic Americans.

Study summary:

Our main hypothesis is that in contrast to non Hispanic whites, the degree of RAAS system activation is more pronounced in Mexican Americans with diastolic HF and consequently their response to RAAS inhibition therapy is greater. Blocking the RAAS with renin inhibitor plus aldosterone receptor blocker should produce measurable changes in biomarkers as well as physiologic improvement that could therefore translate into improved clinical outcomes. These changes should be greater appreciated in Mexican Americans if the central pathophysiologic influence of HF in this population was RAAS maladaptation.


Inclusion Criteria: 1. Chronic stable diastolic HF documented by clinical diagnosis and echocardiogram within the last 2 years 2. NYHA classes I-III, symptomatically stable (for >1month) 3. Age 21-70 years 4. Either of Hispanic ethnicity (Mexican American origin) or non-Hispanic white 5. Patients on ACE inhibitor therapy (lisinopril) 6. Blood pressure >100/75 mmHg 7. Adequate birth control 8. Patients seen in TTUHSC Cardiology or Internal Medicine clinic for at least two visits since January 2008 Exclusion Criteria: 1. Acute coronary syndrome (within the last month). 2. Recent acute diastolic or systolic HF (within the last month) 3. Pancreatic disease 4. Renal artery stenosis 5. Pregnancy 6. History of angioedema 7. Severe hypotension (systolic BP<90mmHg or mean arterial pressure <65mmHg) 8. Hyperkalemia (defined by K+>5 mEq/L) 9. Chronic Kidney Disease (Stage 3 and above) 10. Systolic dysfunction (ejection fraction below 50%) 11. Ethnicity other than Mexican American or non-Hispanic white



Primary Contact:


Backup Contact:


Location Contact:

Lubbock, Texas 79430
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.